Cognitive fluctuations are a defining feature of dementia with Lewy bodies (DLB), helping distinguish it from Alzheimer’s disease — but they remain notoriously difficult to characterize and measure. A 2026 review by Mahajan and colleagues maps the neurobiology, measurement, and clinical implications of fluctuations across the Lewy body spectrum.1 Research Highlights Cognitive fluctuations are episodes …
Psychedelic-assisted therapy has been one of the most-covered mental-health stories of the past decade. A 2026 quantitative analysis by Evers and colleagues maps how media enthusiasm grew, peaked, and partially pulled back across major U.S. outlets — and how the coverage related to the actual evidence base for depression and PTSD.1 Research Highlights Psychedelic clinical …
Lisdexamfetamine remains the only FDA-approved medication for binge-eating disorder — a serious condition affecting roughly 1.2% of adults. A 2026 human laboratory study by McKee and colleagues tests whether naltrexone/bupropion, already approved for obesity, reduces the food-reward mechanisms that drive binge episodes.1 Research Highlights Binge-eating disorder (BED) is the most common eating disorder in the …
Chronic low-grade inflammation rises with age, and a growing body of work asks whether peripheral inflammatory markers in blood track subtle changes in brain white-matter microstructure on MRI. A 2026 preprint from the Healthy Minds for Life cohort by Mishra and colleagues at Johns Hopkins examined 457 dementia-free adults aged 50–79 and found that higher …
The dopamine hypothesis of schizophrenia is the field’s longest-running mechanistic story, and most of its supporting evidence has been cross-sectional. A 2026 longitudinal PET study by Schulz and colleagues followed the same 28 patients across psychosis and early remission.1 Research Highlights The dopamine hypothesis of schizophrenia is the field’s longest-running mechanistic story. Cross-sectional 18F-DOPA PET …
PTSD and major depressive disorder co-occur in roughly half of patients with either diagnosis, and the comorbid presentation is more severe than either alone. The mechanistic question has been whether comorbidity reflects synergistic biology or simple symptom additivity. A 2026 rat-model study by Jiang and colleagues tests this directly, finding that PTSD-MDD comorbid rats show …
“Schizophrenia ages you faster” is the headline that gets repeated whenever a new biomarker study lands. The 2026 Fernandez-Egea, Garcia-Rizo and Kirkpatrick review — covering 170 studies across mortality, brain imaging, telomeres, epigenetic clocks, and metabolic markers — pushes back on that framing.2 The aging signal is genuine. “Accelerated” is the part that overshoots for …